Glycerol Monolaurate-Mediated Attenuation of Metabolic Syndrome is Associated with the Modulation of Gut Microbiota in High Fat diet-fed Mice.Mol Nutr Food Res 2019; :e1801417MN
Gut microbiota plays an important role in the development of diet-induced obesity and metabolic syndrome. Glycerol monolaurate (GML), a widely consumed food emulsifier, has been reported to promote metabolic disorder and gut microbiota dysbiosis in low-dose supplementation upon low fat diet feeding. However, little is known about whether GML produce the same effects in mice fed a high fat diet (HFD).
METHODS AND RESULTS
C57BL/6 mice were fed a HFD with or without GML supplementation (150, 300 and 450 mg/kg) for 10 weeks. Our results demonstrated that higher GML treatment (450 mg/kg) ameliorated HFD-induced metabolic disorders, supported by prevented visceral fat deposition, improved serum hyperlipidemia, modulated hepatic lipid metabolism and reduced serum levels of proinflammatory cytokine, TNF-α. Additionally, circulating LPS load and insulin resistance were attenuated by all doses of GML supplementation. Notably, GML ameliorated HFD-induced gut microbiota dysbiosis, with increases in Bacteroides uniformis, Akkermansia, Bifidobacterium and Lactobacillus and decreases in Escherichia coli, Lactococcus and Flexispira. Spearman's correlation analysis indicated that these enriched specific genera are significantly associated with the metabolic improvements of GML.
Our findings identify the links between gut microbiota and GML-induced metabolic improvements, suggesting that the attenuation of HFD-induced metabolic disorders by higher GML supplementation might occur through targeting gut microbiota. This article is protected by copyright. All rights reserved.